Septerna, Inc. (NASDAQ:SEPN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $45.8889.
Several brokerages have recently commented on SEPN. Truist Financial increased their price target on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Guggenheim reduced their price objective on shares of Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, July 1st. Stifel Nicolaus began coverage on shares of Septerna in a report on Friday, May 1st. They issued a “buy” rating and a $43.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Septerna in a research report on Wednesday, July 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th.
Read Our Latest Analysis on SEPN
Septerna Stock Performance
Septerna (NASDAQ:SEPN – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, sell-side analysts forecast that Septerna will post -1.59 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Samira Shaikhly sold 2,178 shares of Septerna stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the sale, the insider owned 793 shares of the company’s stock, valued at approximately $27,897.74. This trade represents a 73.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Daniel D. Long sold 3,333 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $34.36, for a total transaction of $114,521.88. Following the completion of the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,312,716.32. This trade represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 44,494 shares of company stock valued at $1,469,391. 5.80% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Septerna
Hedge funds and other institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC grew its position in Septerna by 18.0% in the first quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock valued at $17,611,000 after acquiring an additional 112,049 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Septerna in the 1st quarter valued at $619,000. Swiss National Bank acquired a new stake in shares of Septerna in the 1st quarter valued at $531,000. Renaissance Technologies LLC bought a new stake in shares of Septerna in the 1st quarter worth about $906,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Septerna by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after purchasing an additional 3,377 shares during the last quarter.
Septerna Company Profile
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Featured Stories
- Five stocks we like better than Septerna
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
